{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:59:55Z","timestamp":1791125995169,"version":"4.1.0"},"reference-count":214,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T00:00:00Z","timestamp":1386288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Many approaches are used to discover new antibiotic compounds, one of the most widespread being the chemical modification of known antibiotics. This type of discovery has been so important in the development of new antibiotics that most antibiotics used today belong to the same chemical classes as antibiotics discovered in the 1950s and 1960s. Even though the discovery of new classes of antibiotics is urgently needed, the chemical modification of antibiotics in known classes is still widely used to discover new antibiotics, resulting in a great number of compounds in the discovery and clinical pipeline that belong to existing classes. In this scenario, the present article presents an overview of the R&amp;D pipeline of new antibiotics in known classes of antibiotics, from discovery to clinical trial, in order to map out the technological trends in this type of antibiotic R&amp;D, aiming to identify the chemical classes attracting most interest, their spectrum of activity, and the new subclasses under development. The result of the study shows that the new antibiotics in the pipeline belong to the following chemical classes: quinolones, aminoglycosides, macrolides, oxazolidinones, tetracyclines, pleuromutilins, beta-lactams, lipoglycopeptides, polymyxins and cyclic lipopeptides.<\/jats:p>","DOI":"10.3390\/antibiotics2040500","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T12:12:35Z","timestamp":1386331955000},"page":"500-534","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Pipeline of Known Chemical Classes of Antibiotics"],"prefix":"10.3390","volume":"2","author":[{"given":"Cristina","family":"De Souza Mendes","sequence":"first","affiliation":[{"name":"Graduate Program in Technology of Chemical and Biochemical Processes, Technology Center, Federal University of Rio de Janeiro (UFRJ), EQ\/UFRJ, Centro de Tecnologia, Bloco E,  Ilha do Fund\u00e3o, Rio de Janeiro-RJ 21949-900, Brazil"},{"name":"Brazilian National Institute of Industrial Property, INPI\/Rua Mayrink Veiga No. 9\/19 andar,  CEP 20090-910, Rio de Janeiro-RJ 20090-910, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide","family":"De Souza Antunes","sequence":"additional","affiliation":[{"name":"Graduate Program in Technology of Chemical and Biochemical Processes, Technology Center, Federal University of Rio de Janeiro (UFRJ), EQ\/UFRJ, Centro de Tecnologia, Bloco E,  Ilha do Fund\u00e3o, Rio de Janeiro-RJ 21949-900, Brazil"},{"name":"Brazilian National Institute of Industrial Property, INPI\/Rua Mayrink Veiga No. 9\/19 andar,  CEP 20090-910, Rio de Janeiro-RJ 20090-910, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2013,12,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1126\/science.1176667","article-title":"Antibiotics for emerging pathogens","volume":"325","author":"Fischbach","year":"2009","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Walsh, C., and Wencewicz, T. (2013). Prospects for new antibiotics: A molecule-centered perspective. J. Antibiot.","DOI":"10.1038\/ja.2013.49"},{"key":"ref_3","first-page":"943","article-title":"New perspectives on antibacterial drug research","volume":"8","author":"Ziemska","year":"2013","journal-title":"Cent. Eur. J. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/cid\/cit152","article-title":"10 \u00d7 '20 Progress\u2014Development of new drugs active against Gram-negative bacilli: An update from the infectious diseases society of America","volume":"56","author":"Boucher","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Bassetti, M., Merelli, M., Temperoni, C., and Astilean, A. (2013). New antibiotics for bad bugs: Where are we?. Ann. Clin. Microbiol. Antimicrob., 12.","DOI":"10.1186\/1476-0711-12-22"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/157489112803521922","article-title":"Novel antimicrobial agents against multi-drug-resistant Gram-negative bacteria: An overview","volume":"7","author":"Karras","year":"2012","journal-title":"Recent Pat. Antiinfect. Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2174\/157489112803521959","article-title":"Novel antimicrobial agents against multi-drug-resistant Gram-positive bacteria: An overview","volume":"7","author":"Giannakaki","year":"2012","journal-title":"Recent Pat. Antiinfect. Drug Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.coph.2012.06.003","article-title":"Improving known classes of antibiotics: An optimistic approach for the future","volume":"12","author":"Bush","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Butler, M.S., Blaskovich, M.A., and Cooper, M.A. (2013). Antibiotics in the clinical pipeline in 2013. J. Antibiot.","DOI":"10.1038\/ja.2013.86"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(02)11394-8","article-title":"The pharmaceutical industry as an informant","volume":"360","author":"Collier","year":"2002","journal-title":"Lancet"},{"key":"ref_11","unstructured":"World Health Organization WHO International Clinical Trials Registry Platform (ICTRP). Available online:http:\/\/www.who.int\/ictrp\/en\/."},{"key":"ref_12","unstructured":"Dialog LLC Chemical Business NewsBase (CBNB)\u2014Bluesheet. Available online:http:\/\/library.dialog.com\/bluesheets\/html\/bl0319.html."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/11632780-000000000-00000","article-title":"Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses","volume":"32","author":"Beining","year":"2012","journal-title":"Clin. Drug Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1128\/AAC.00683-09","article-title":"Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers","volume":"54","author":"Chung","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","unstructured":"TaiGen Biotechnology Study to evaluate the efficacy and safety of oral administration with nemonoxacin and levofloxacin in patients with CAP. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01529476."},{"key":"ref_16","unstructured":"TaiGen Biotechnology Safety and efficacy study of TG-873870 (Nemonoxacin) in diabetic foot infections. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00685698."},{"key":"ref_17","unstructured":"TaiGen Biotechnology Nemonoxacin: Once-a-day oral and IV, with excellent activity toward MRSA and VRSA. Available online:http:\/\/www.taigenbiotech.com.tw\/research.html."},{"key":"ref_18","unstructured":"TaiGen Biotechnology TaiGen Biotechnology announces submission of new drug application for nemonoxacin in Taiwan and China. Available online:http:\/\/www.taigenbiotech.com.tw\/news.html#25."},{"key":"ref_19","unstructured":"Ferrer Group Key development projects. Available online:http:\/\/www.ferrergrupo.com\/Innovation_Innovacion-Pipeline-de-proyectos-ENG."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/jac\/49.3.455","article-title":"In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone","volume":"49","author":"Yamakawa","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_21","unstructured":"Ferrer Internacional Efficacy and safety of ozenoxacin 1% cream versus placebo in the treatment of patients with impetigo. Available online:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01397461."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1128\/AAC.00153-06","article-title":"Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents","volume":"50","author":"Credito","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1128\/AAC.01407-05","article-title":"In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone","volume":"50","author":"Park","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","unstructured":"Dong Wha Pharmaceutical Co. Ltd. A study to evaluate efficacy and safety profile of Zabofloxacin tablet 400 mg and moxifloxacin tablet 400 mg. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01658020."},{"key":"ref_25","unstructured":"Dong Wha Pharmaceutical Co. Ltd. A new quinolone antibiotic. Available online:http:\/\/www.dong-wha.co.kr\/english\/rnd\/rnd02_03.asp."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1093\/jac\/dks307","article-title":"Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: Resistance selection and characterization","volume":"67","author":"Remy","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_27","unstructured":"Rib-X Pharmaceuticals Delafloxacin. Available online:http:\/\/www.rib-x.com\/pipeline\/delafloxacin.php."},{"key":"ref_28","unstructured":"Otsuka Pharmaceutical Delafloxacin versus vancomycin and aztreonam for the treatment of acute bacterial skin and skin structure infections. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01811732."},{"key":"ref_29","unstructured":"Furiex Pharmaceuticals Efficacy and safety study of JNJ-32729463 compared with moxifloxacin for the treatment of subjects requiring hospitalization for community-acquired bacterial pneumonia. Available online:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01198626."},{"key":"ref_30","unstructured":"Furiex Pharmaceuticals Efficacy and safety study of JNJ-32729463 for treating complicated skin and skin structure infections compared to linezolid (zyvox). Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01128530."},{"key":"ref_31","unstructured":"Furiex JNJ-Q2 best-in-class, broad-spectrum fluoroquinolone with potent MRSA coverage. Available online:http:\/\/www.furiex.com\/wp-content\/uploads\/2011\/07\/JNJ-Q2_Info-Sheet-JUNE-2011.pdf."},{"key":"ref_32","unstructured":"Furiex Furiex receives qualified infectious disease product and fast track designations from  the U.S. Food and Drug Administration for Avarofloxacin (JNJ-Q2). Available online:http:\/\/investor.furiex.com\/releasedetail.cfm?ReleaseID=742926."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijantimicag.2011.11.016","article-title":"Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia","volume":"39","author":"Biedenbach","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1128\/AAC.05044-11","article-title":"Randomized, double-blind, phase II, multicenter study evaluating the safety\/ tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection","volume":"55","author":"Covington","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1128\/AAC.01374-09","article-title":"In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone","volume":"54","author":"Morrow","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","unstructured":"Durata Therapeutics, Inc. Finafloxacin for the treatment of cUTI and\/or acute pyelonephritis. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01928433."},{"key":"ref_37","unstructured":"Merlion Pharma A multi-dose, double-blind, double-dummy, active control, randomized clinical (Phase II) study of two dosing regimens of finafloxacin for the treatment of cUTI and\/or acute pyelonephritis. Available online:http:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011\u2013006041\u201314\/PL\/."},{"key":"ref_38","unstructured":"Pharma, M. (2013). FDA Grants Qualified Infectious Disease Product Designation and Fast Track Status for MerLion Pharma\u2019s Lead Antibacterial Candidate Finafloxacin, Merlion Pharma."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijantimicag.2011.03.002","article-title":"Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila","volume":"38","author":"Lemaire","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1093\/jac\/dks213","article-title":"2012 and beyond: Potential for the start of a second pre-antibiotic era?","volume":"67","author":"Appelbaum","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_41","unstructured":"Wockhardt Limited Phase II open label, multi-centeric clinical trial of oral WCK 2349 (1000 mg bid and 1200 mg bid) to evaluate safety and efficacy in the treatment of complicated skin and soft tissue infections caused by gram positive bacteria. Available online:http:\/\/www.ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=1797."},{"key":"ref_42","unstructured":"Wockhardt New chemical entity pipeline. Available online:http:\/\/www.wockhardt.com\/how-we-touch-lives\/new-drug-discover.aspx."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1128\/AAC.48.8.3188-3192.2004","article-title":"Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents","volume":"48","author":"Peric","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","unstructured":"Kyorin Kyorin\u2014Main R&D Activities-1 (4 February 2013 Release). Available online:http:\/\/www.kyorin-pharm.co.jp\/en\/business\/pdf\/main_rd_activities_20130204_en.pdf."},{"key":"ref_45","unstructured":"Kyorin Drug discovery, development, and lcm with medical professionals and patients in mind. Available online:http:\/\/www.kyorin-gr.co.jp\/en\/business\/gensen\/r_and_d.shtml."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Higuchi, S., Onodera, Y., Chiba, M., Hoshino, K., and Gotoh, N. (2013). Potent in vitro antibacterial activity of DS-8587, a new generation of broad spectrum quinolone, against Acinetobacter baumannii. Antimicrob. Agents Chemother.","DOI":"10.1128\/AAC.02374-12"},{"key":"ref_47","unstructured":"Daiichi Sankyo Major R&D pipeline as of July, 2013. Available online:http:\/\/www.daiichisankyo.com\/rd\/pipeline\/pdf\/Pipeline_EN.pdf."},{"key":"ref_48","unstructured":"Achillion Pharmaceuticals About ACH-702. Available online:http:\/\/www.achillion.com\/PL\/pdf\/04_ach_702_bg.pdf."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1128\/AAC.01666-10","article-title":"In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens","volume":"55","author":"Pucci","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","unstructured":"Achaogen Study for the treatment of complicated urinary tract infection and acute pyelonephritis. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01096849."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1586\/eri.12.25","article-title":"Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin","volume":"10","author":"Zhanel","year":"2012","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1128\/AAC.00556-09","article-title":"ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates","volume":"53","author":"Endimiani","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","unstructured":"Achaogen Achaogen pipeline. Available online:http:\/\/www.achaogen.com."},{"key":"ref_54","unstructured":"Achaogen Achaogen Awarded $60M Contract Option by BARDA for the Clinical Development of Plazomicin. Available online:http:\/\/www.achaogen.com\/news\/151\/15."},{"key":"ref_55","unstructured":"Achaogen Achaogen announces all objectives met in Phase 2 Plazomicin complicated urinary tract infections study and start of first-in-human study with ACHN-975. Available online:http:\/\/www.achaogen.com\/uploads\/news\/id148\/Achaogen_PressRelease_2012\u201305\u201315.pdf."},{"key":"ref_56","unstructured":"Achaogen (2013). Achaogen Announces Agreement with FDA on a Special Protocol Assessment for a Phase 3 Clinical Trial of Plazomicin to Treat Infections Caused by Carbapenem-Resistant Enterobacteriaceae (CRE), Achaogen."},{"key":"ref_57","unstructured":"Achaogen Next-generation aminoglycosides. Available online:http:\/\/www.achaogen.com\/pipeline\/next-generation-aminoglycosides."},{"key":"ref_58","unstructured":"Maianti, J.P., Aggen, J.B., Dozzo, P., Goldblum, A.A., Hildebrandt, D.J., Kane, T.R., Gliedt, M.J., Linsell, M.S., Hanessian, S., and Giguere, A. (2011). Antibacterial Aminoglycoside Analogs. (WO2011044498A1)."},{"key":"ref_59","unstructured":"Dozzo, P., Goldblum, A.A., and Aggen, J.B. (2011). Antibacterial Aminoglycoside Analogs. (WO2011044502A1)."},{"key":"ref_60","unstructured":"Aggen, J.B., Goldblum, A.A., Dozzo, P., Hildebrandt, D.J., Kane, T.R., Gliedt, M.J., and Linsell, M.S. (2011). Antibacterial Aminoglycoside Analogs. (WO2011044503A1)."},{"key":"ref_61","unstructured":"Aggen, J.B., Dozzo, P., Goldblum, A.A., Hildebrandt, D.J., Kane, T.R., Gliedt, M.J., and Linsell, M.S. (2011). Antibacterial Aminoglycoside Analogs. (WO2011044538A1)."},{"key":"ref_62","unstructured":"Aggen, J.B., Dozzo, P., Goldblum, A.A., Hildebrandt, D.J., Kane, T.R., Gliedt, M.J., and Linsell, M.S. (2011). Antibacterial Aminoglycoside Analogs. (WO2011044501A2)."},{"key":"ref_63","unstructured":"Goldblum, A.A., Dozzo, P., Kane, T.R., Aggen, J.B., Linsell, M.S., Hildebrandt, D.J., and Gliedt, M.J. (2012). Antibacterial Aminoglycoside Analogs. (US20120122809A1)."},{"key":"ref_64","unstructured":"Changzhou Fangyuan Pharmaceutical Achievements Introduced. Available online:http:\/\/s2.shenjian.net\/Cn_about_ID13.html."},{"key":"ref_65","unstructured":"Changzhou Fangyuan Pharmaceutical Jiangsu a semi-sinthetic antibiotic engeenering technology research center. Available online:http:\/\/s2.shenjian.net\/Cn_about_ID13.html."},{"key":"ref_66","unstructured":"Cempra Pharmaceuticals Solithromycin (CEM-101). Available online:http:\/\/www.cempra.com\/products\/Solithromycin-cem-101\/."},{"key":"ref_67","unstructured":"Cempra Pharmaceuticals Efficacy and safety study of oral solithromycin (CEM-101) compared to oral moxifloxacin in treatment of patients with community-acquired bacterial pneumonia. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01756339."},{"key":"ref_68","unstructured":"Cempra Pharmaceuticals Safety and efficacy study of single-dose oral CEM-101 in patients with uncomplicated urogenital gonorrhea. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01591447."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1128\/AAC.00203-09","article-title":"Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in Human THP-1 macrophages","volume":"53","author":"Lemaire","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1128\/AAC.01123-09","article-title":"In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms","volume":"54","author":"McGhee","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1358\/dof.2011.36.10.1622079","article-title":"Solithromycin: Macrolide antibiotic","volume":"36","author":"Fernandes","year":"2011","journal-title":"Drugs Future"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1128\/AAC.00197-13","article-title":"Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia","volume":"57","author":"Oldach","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_73","unstructured":"Cempra Pharmaceuticals Preclinical programs\u2014About macrolides. Available online:http:\/\/www.cempra.com\/preclinical-programs\/about-macrolides\/."},{"key":"ref_74","unstructured":"Pereira, D.E. (2012). Hydrogen Bond Forming Fluoro Ketolides for Treating Diseases. (WO2012034058A1)."},{"key":"ref_75","unstructured":"Enanta Pharmaceuticals EDP-788\/EDP-322. Available online:http:\/\/www.enanta.com\/research\/antibiotics\/."},{"key":"ref_76","unstructured":"Enanta Pharmaceuticals (2013). Enanta Pharmaceuticals Announces National Institute of Allergy and Infectious Diseases (NIAID) Will Fund Further Development of a Novel Bicyclolide, Business Wire."},{"key":"ref_77","unstructured":"Enanta Pharmaceuticals Bicyclolide antibiotics. Available online:http:\/\/www.enanta.com\/research\/antibiotics\/."},{"key":"ref_78","unstructured":"Enanta Pharmaceuticals Enanta reports new macrolide-related drug class, bicyclolides, to combat hospital and community acquired superbug infections, including MRSA. Available online:http:\/\/www.prnewswire.com\/news-releases\/enanta-reports-new-macrolide-related-drug-class-bicyclolides-to-combat-hospital-and-community-acquired-superbug-infections-including-mrsa-57361732.html."},{"key":"ref_79","unstructured":"Wang, G., Xu, G., Or, Y.S., Gang, L., Niu, D., Fu, H., Qui, Y., Wang, Y., Basayek, M., and Peng, Y. (2011). New 6\u201311 Bicyclic Macrolide Derivative Useful in Pharmaceutical Composition for Preventing and\/or Treating Bacterial Infection in Humans. (CN101955508-A)."},{"key":"ref_80","unstructured":"Kim, I.J., Liu, T., Long, J., Wang, G., Qiu, Y., Kim, H., Wang, Y., Phan, L.T., and Or, Y.S. (2013). 6,11-Bridged Biaryl Macrolides. (US2013165641-A1)."},{"key":"ref_81","unstructured":"Wockhardt New chemical entities pipeline strategic focus on sepsis and antiinfectives. Available online:http:\/\/www.wockhardt.com\/how-we-touch-lives\/new-drug-discover.aspx."},{"key":"ref_82","unstructured":"Wockhardt Wockhardt annual report 2011\u20132012. Available online:http:\/\/www.wockhardt.com\/pdf\/Annual-Report-2011\u20132012-f932f.pdf."},{"key":"ref_83","unstructured":"Rib-X Pharmaceuticals Discovery programs\u2014RX-02. Available online:http:\/\/www.rib-x.com\/pipeline\/discovery-programs.php."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1128\/AAC.00571-06","article-title":"In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis","volume":"50","author":"Gonzalez","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1128\/AAC.00458-12","article-title":"In vitro activity and microbiological efficacy of Tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral Tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections","volume":"56","author":"Prokocimer","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs. linezolid for treatment of acute bacterial skin and skin structure infections: The establish-1 randomized trial","volume":"309","author":"Prokocimer","year":"2003","journal-title":"JAMA"},{"key":"ref_87","unstructured":"Trius Therapeutics TR-701 FA vs. linezolid for the treatment of acute bacterial skin and skin structure infections. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01421511."},{"key":"ref_88","unstructured":"Smith, L. Trius: Clinical trials show important differentiation of tedizolid from zyvox (TSRX, $6.48). Available online:http:\/\/smithonstocks.com\/trius-clinical-trials-show-important-differentiation-of-tedizolid-from-zyvox-tsrx-6\u201348\/."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ja.2013.27","article-title":"Speculative strategies for new antibacterials: All roads should not lead to Rome","volume":"66","author":"Shapiro","year":"2013","journal-title":"J. Antibiot. (Tokyo)"},{"key":"ref_90","unstructured":"Actelion Pharmaceuticals Cadazolid. Available online:http:\/\/www1.actelion.com\/en\/scientists\/development-pipeline\/phase-3\/cadazolid.page."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Chilton, C.H., Crowther, G.S., Baines, S.D., Todhunter, S.L., Freeman, J., Locher, H.H., Athanasiou, A., and Wilcox, M.H. (2013). In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J. Antimicrob. Chemother.","DOI":"10.1093\/jac\/dkt411"},{"key":"ref_92","unstructured":"Rempex Pharmaceuticals ACT-179811 in patients with Clostridium difficile infection (CDI). Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01222702."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1749-6632.2011.06323.x","article-title":"Antibiotics in development targeting protein synthesis","volume":"1241","author":"Sutcliffe","year":"2011","journal-title":"Ann. NY Acad. Sci."},{"key":"ref_94","unstructured":"Rib-X Radezolid. Available online:http:\/\/www.rib-x.com\/pipeline\/radezolid.php#development."},{"key":"ref_95","unstructured":"Rib-X Pharmaceuticals, Inc. Safety and efficacy study of oxazolidinone to treat pneumonia. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00640926."},{"key":"ref_96","unstructured":"Rib-X Pharmaceuticals, Inc. Safety and efficacy study of oxazolidinones to treat uncomplicated skin infections. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00646958."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.2011.06330.x","article-title":"The oxazolidinones: Past, present, and future","volume":"1241","author":"Shaw","year":"2011","journal-title":"Ann. NY Acad. Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1128\/AAC.01193-07","article-title":"R\u03c7-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance","volume":"52","author":"Skripkin","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_99","unstructured":"AstraZeneca New tuberculosis drug trial begins in South Africa. Available online:http:\/\/www.astrazeneca.com\/Research\/news\/Article\/20121210--new-tuberculosis-drug-trial-begins-in-south-africa."},{"key":"ref_100","unstructured":"Working Group on New TB Drugs AZD5847 oxazolidinone. Available online:http:\/\/www.newtbdrugs.org\/project.php?id=174."},{"key":"ref_101","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID) Phase 2a EBA trial of AZD5847. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01516203."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2012.02.033","article-title":"Tuberculosis: The drug development pipeline at a glance","volume":"51","author":"Villemagne","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1128\/AAC.00723-10","article-title":"In vitro and In vivo activities of LCB01\u20130371, a new oxazolidinone","volume":"54","author":"Jeong","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_104","unstructured":"LegoChem Biosciences Multiple ascendoing dose study for LCB01\u20130371. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01842516."},{"key":"ref_105","unstructured":"MicuRx Pharmaceuticals, Inc. MicuRx and Shanghai Zhangjiang biomedical industry venture capital partner to develop next-generation antibiotic MRX-I for Chinese market. Available online:http:\/\/www.micurx.com\/doc\/10-24-12%20JV-FINAL.doc."},{"key":"ref_106","unstructured":"MicuRx Pharmaceuticals Discovery and development. Available online:http:\/\/www.micurx.com\/d1.htm."},{"key":"ref_107","unstructured":"Paratek About Paratek. Available online:http:\/\/www.paratekpharm.com\/."},{"key":"ref_108","unstructured":"Paratek Paratek Pharmaceuticals announces FDA Grant of Qualified Infectious Disease Product (QIDP) designation for its lead product candidate, Omadacycline\u2014QIDP status designated for both intravenous and oral formulations. Available online:http:\/\/www.paratekpharm.com\/press\/010313%20Paratek%20QIDP%20Press%20Release.pdf."},{"key":"ref_109","unstructured":"Tetraphase Pharmaceuticals Tetraphase pipeline\u2014Overview. Available online:http:\/\/tphase.com\/pipeline\/overview\/default.cfm#tp271."},{"key":"ref_110","unstructured":"Tetraphase Pharmaceuticals Study to compare TP-434 and Ertapenem in CA complicated intra-abdominal infections. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01265784."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1128\/AAC.06187-11","article-title":"Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic","volume":"56","author":"Grossman","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1021\/op4000219","article-title":"Process R&D of Eravacycline: The first fully synthetic fluorocycline in clinical development","volume":"17","author":"Ronn","year":"2013","journal-title":"Org. Process Res. Dev."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1128\/AAC.00743-12","article-title":"In vitro activity of TP-271 against Mycobacterium abscessus, Mycobacterium fortuitum, and Nocardia Species","volume":"56","author":"Cynamon","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_114","unstructured":"Grossman, T., Hunt, D., Heine III, H., and Sutcliffe, J. (2010, January 12\u201315). TP-271, a novel oral fluorocycline for community-acquired respiratory and biothreat pathogens. Proceedings of 50th International Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA."},{"key":"ref_115","unstructured":"Tetraphase Our technology. Available online:http:\/\/tphase.com\/technology\/our_technology\/default.cfm."},{"key":"ref_116","unstructured":"Chen, C.-L., Clark, R.B., Deng, Y., Plamondon, L., Sun, C., and Xiao, X.-Y. (2012). Tetracycline Analogs. (WO2012021712A1)."},{"key":"ref_117","unstructured":"Xiao, X.-Y., Clark, R., Hunt, D., Roenn, M., Plamondon, L., He, M., Sutcliffe, J., and Grossman, T. (2011). Polycyclic Tetracycline Compounds. (WO2011123536A1)."},{"key":"ref_118","unstructured":"Deng, Y., Plamondon, L., Sun, C., Xiao, X.-Y., Zhou, J., Sutcliffe, J.A., and Ronn, M.P. (2011). Tetracycline Compounds. (WO2011025982A2)."},{"key":"ref_119","unstructured":"Nabriva Pleuromutilins. Available online:http:\/\/www.nabriva.com\/programs\/pleuromutilins\/."},{"key":"ref_120","unstructured":"Forest Laboratories Our pipeline: Solid, and set for further growth. Available online:http:\/\/www.frx.com\/research\/pipeline.aspx."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1128\/AAC.05789-11","article-title":"Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections","volume":"56","author":"Sader","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/jac\/dks001","article-title":"Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)","volume":"67","author":"Sader","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_123","unstructured":"Nabriva Therapeutics AG Study comparing the safety and efficacy of two doses of BC-3781 vs. vancomycin in patients with acute bacterial skin and skin structure infection (ABSSSI). Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01119105."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1749-6632.2011.06219.x","article-title":"Are pleuromutilin antibiotics finally fit for human use?","volume":"1241","author":"Novak","year":"2011","journal-title":"Ann. NY Acad. Sci."},{"key":"ref_125","unstructured":"Riedl, R., Thirring, K., and Heilmayer, W. (2012). Pleuromutilin Derivatives for Use in the Treatment of Diseases Mediated by Microbes. (WO2012031307A1)."},{"key":"ref_126","unstructured":"Mang, R., Thirring, K., and Heilmayer, W. (2012). Pleuromutilin Derivatives for Use in the Treatment of Diseases Mediated by Microbes. (EP2433926A1)."},{"key":"ref_127","unstructured":"Heilmayer, W., Mang, R., Badegruber, R., Stickmann, D., Novak, R., Ferencic, M., and Bulusu, A.R.C.M. (2012). Pleuromutilin Derivatives for the Treatment of Diseases Mediated by Microbes. (MX2010009451A)."},{"key":"ref_128","first-page":"100","article-title":"Antibiotheraphy in the 21st century, antibacterials for the second decade. Posibilities or realities in the future?","volume":"25","year":"2012","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_129","unstructured":"Cubist Pharmaceuticals Safety and efficacy of intravenous CXA-201 and intravenous meropenem in complicated intraabdominal infections. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01445665."},{"key":"ref_130","unstructured":"Cubist Pharmaceuticals Study comparing the safety and efficacy of intravenous CXA-201 and intravenous levofloxacin in complicated urinary tract infection, including pyelonephritis. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01345955."},{"key":"ref_131","unstructured":"Cubist Pharmaceuticals Study comparing the safety and efficacy of intravenous CXA-201 and intravenous meropenem in complicated intraabdominal infections. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01445678."},{"key":"ref_132","unstructured":"Cubist Pharmaceuticals Ceftolozane\/tazobactam overview. Available online:http:\/\/www.cubist.com\/products\/cxa_201."},{"key":"ref_133","unstructured":"Basilea Pharmaceutica (2013). Basilea Awarded Contract by BARDA of Up to USD 89 Million for the Development of Its Novel Antibiotic BAL30072, Basilea Pharmaceutica Ltd."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1128\/AAC.01525-09","article-title":"In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli","volume":"54","author":"Page","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_135","unstructured":"Basilea Pharmaceutica Basilea Pharmaceutica Ltd. Annual Report 2012. Available online:http:\/\/annualreport.basilea.com\/downloads\/Basilea_AR12_E.pdf."},{"key":"ref_136","unstructured":"Shionogi Pipeline (as of August 2013). Available online:http:\/\/www.shionogi.co.jp\/en\/company\/pmrltj0000000u4v-att\/e_kaihatsu.pdf."},{"key":"ref_137","unstructured":"Shionogi Research and development at Shionogi. Available online:http:\/\/www.shionogi.com\/pdf\/RDmeeting2012.pdf."},{"key":"ref_138","unstructured":"GlaxoSmithKline GlaxoSmithKline product development pipeline 2013. Available online:http:\/\/www.gsk.com\/content\/dam\/gsk\/globals\/documents\/pdf\/GSK%202013%20Pipeline.pdf."},{"key":"ref_139","unstructured":"Cubist Pharmaceuticals Cubist to Feature Antibiotic Development Programs at 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Available online:http:\/\/www.businesswire.com\/news\/home\/20120906005268\/en\/Cubist-Feature-Antibiotic-Development-Programs-52nd-Annual."},{"key":"ref_140","unstructured":"Joo, H., Choi, W.-B., Kim, D.-I., Kowalik, S., Mao, E., Li, Y., Liu, S., and Hager, M.W. (2013, January 11). FSI-1671, a Novel Anti-Acinetobacter Carbapenem; in vitro Activity of FSI-1671 and FSI-1671\/Sulbactam against MDR-A.baumannii. Proceedings of 53rd International Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, USA."},{"key":"ref_141","unstructured":"Joo, H., Choi, W.-B., Kim, D.-I., Kowalik, E., Hager, M.W., Mao, S., Li, Y., and Liu, S. (2013, January 11). FSI-1671, a Novel Anti-Acinetobacter Carbapenem; in vivo Efficacy against Carbapenem-Resistance Gram-Negative Bacterial Infection. Proceedings of 53rd International Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, USA."},{"key":"ref_142","unstructured":"AstraZeneca Compare ceftazidime-avibactam and doripenem followed by oral therapy for hospitalized adults with complicated UTIs (Urinary Tract Infections). Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01599806."},{"key":"ref_143","unstructured":"AstraZeneca Our Pipeline\u2014Development pipeline as at 31 December 2012. Available online:http:\/\/www.astrazeneca.com\/Research\/Our-pipeline-summary."},{"key":"ref_144","unstructured":"AstraZeneca, and Cerexa, Inc. Ceftazidime-Avibactam for the treatment of infections due to ceftazidime resistant pathogens. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01644643."},{"key":"ref_145","unstructured":"AstraZeneca, and Cerexa, Inc. Ceftazidime-Avibactam compared with doripenem followed by oral therapy for hospitalized adults with complicated UTIs (Urinary Tract Infections). Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01595438."},{"key":"ref_146","unstructured":"AstraZeneca, and Cerexa, Inc. A study comparing Ceftazidime-Avibactam + Metronidazole versus Meropenem in adults with complicated intra-abdominal infections. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01500239."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.mib.2011.07.026","article-title":"Diazabicyclooctanes (DBOs): A potent new class of non-beta-lactam beta-lactamase inhibitors","volume":"14","author":"Coleman","year":"2011","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/nyas.12010","article-title":"New \u03b2-lactam-\u03b2-lactamase inhibitor combinations in clinical development","volume":"1277","author":"Shlaes","year":"2013","journal-title":"Ann. NY Acad. Sci."},{"key":"ref_149","unstructured":"Cerexa, Inc. Comparative study of coadministered ceftaroline fosamil and NXL104 vs. intravenous doripenem in adult subjects with complicated Urinary Tract Infections. Available online:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01281462."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1128\/AAC.02134-12","article-title":"Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects","volume":"57","author":"Riccobene","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1128\/AAC.00817-12","article-title":"Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more \u03b2-lactamases and methicillin-resistant Staphylococcus aureus carrying various Staphylococcal cassette chromosome mec types","volume":"56","author":"Castanheira","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_152","unstructured":"Merck Merck pipeline. Available online:http:\/\/www.merck.com\/research\/pipeline\/home.html."},{"key":"ref_153","unstructured":"Merck & Co. Inc. Study of the safety, tolerability, and efficacy of MK-7655 + Imipenem\/ Cilastatin versus Imipenem\/Cilastatin Alone for the treatment of complicated Urinary Tract Infection (cUTI) (MK-7655\u2013003 AM4). Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01505634."},{"key":"ref_154","unstructured":"Merck & Co. Inc. Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem\/ Cilastatin versus Imipenem\/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655\u2013004 AM2). Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01506271."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1128\/AAC.05927-11","article-title":"In vitro activity of MK-7655, a novel \u03b2-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria","volume":"56","author":"Hirsch","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_156","unstructured":"Mendes, R.E., Rhomberg, P.R., Becker, H.K., and Jones, R.N. (2013, January 12). Activity of \u03b2-Lactam agents tested in combination with novel \u03b2-lactamase inhibitor compounds against enterobacteriaceae producing extended-spectrum \u03b2-Lactamases. Proceedings of 53nd International Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, USA."},{"key":"ref_157","unstructured":"Fedora Pharmaceuticals (2013). Fedora Pharmaceuticals Demonstrates that FPI-1465 Increases Activity of Certain Antibiotics against Drug-Resistant Bacteria, Fedora Pharmaceuticals."},{"key":"ref_158","unstructured":"Shlaes, D.M. Antibiotics, ICAAC and Bronchitis. Available online:http:\/\/antibiotics-theperfectstorm.blogspot.com.br\/2012\/09\/antibiotics-icaac-and-bronchitis.html."},{"key":"ref_159","unstructured":"Rempex Abstracts were Published as Part of the 52nd ICAAC, September 2012, San Francisco, CA, USA. Available online:http:\/\/www.rempexpharma.com\/pubs\/icaac2012abstracts."},{"key":"ref_160","unstructured":"Rempex Pharmaceuticals Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01772836."},{"key":"ref_161","unstructured":"Rempex Pharmaceuticals Safety, tolerability, pharmacokinetics of intravenous RPX7009 in healthy adult subjects. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01751269."},{"key":"ref_162","unstructured":"Martell, L.A., Rahil, G., Vaisburg, A., Young, K., Hickey, E., Hermes, J., Dininno, F., and Besterman, J.M. (2009, January 14). A Novel Beta-Lactamase Inhibitor Potentiates and Extends the Antibacterial Activity of Imipenem against \u03b2-Lactam-Resistant P. aeruginosa and K. pneumoniae. Proceedings of 49th ICAAC Annual Meeting, San Francisco, CA, USA."},{"key":"ref_163","unstructured":"Mirati Therapeutics MG96077. Available online:http:\/\/mirati.com\/other-pipeline-assets\/mg96077."},{"key":"ref_164","unstructured":"Durata Therapeutics, Inc. Efficacy and safety of dalbavancin for the treatment of acute bacterial skin and skin structure infections. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01431339."},{"key":"ref_165","unstructured":"Durata Therapeutics Product pipeline dalbavancin overview. Available online:http:\/\/www.duratatherapeutics.com\/product-pipeline\/dalbavancin\/overview."},{"key":"ref_166","unstructured":"Durata Therapeutics Efficacy and Safety of Dalbavancin for the Treatment of ABSSSI. Available online:https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-024042-30\/DE\/."},{"key":"ref_167","unstructured":"Durata Therapeutics Durata therapeutics announces preliminary, topline Phase 3 clinical trial results for dalbavancin in the treatment of ABSSSI. Available online:http:\/\/content.stockpr.com\/_news\/duratatherapeutics\/2013-02-25_Durata_Therapeutics_Announces_Preliminary_Topline_364.pdf."},{"key":"ref_168","unstructured":"Durata Therapeutics Durata therapeutics meets primary endpoints for EMA review in Phase 3 clinical trial. Available online:http:\/\/content.stockpr.com\/_news\/duratatherapeutics\/2013-01-04_Durata_Therapeutics_Meets_Primary_Endpoints_for_EM_343.pdf."},{"key":"ref_169","unstructured":"The Medicines Company Evaluation of the effect of an investigational antibiotic (Oritavancin) in the treatment of skin and skin structure infections compared to a commonly used antibiotic. Available online:https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-021720-10\/GB\/."},{"key":"ref_170","unstructured":"The Medicines Company Oritavancin versus IV vancomycin for the treatment of patients with acute bacterial skin and skin structure infection (SOLO I). Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01252719."},{"key":"ref_171","unstructured":"The Medicines Company Oritavancin versus IV vancomycin for the treatment of patients with acute bacterial skin and skin structure infection (SOLO II). Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01252732."},{"key":"ref_172","unstructured":"The Medicines Company Product Development is Innovation. Available online:http:\/\/www.themedicinescompany.com\/page\/pipeline."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2146\/ajhp110572","article-title":"Oritavancin: An investigational lipoglycopeptide antibiotic","volume":"70","author":"Karaoui","year":"2013","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1517\/13543776.2010.511177","article-title":"New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile","volume":"20","author":"Johnson","year":"2010","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/jac\/dks438","article-title":"Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens","volume":"68","author":"Vaara","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_176","unstructured":"Northern Antibiotics Northern antibiotics fights against multi-resistant gram-negatives. Available online:http:\/\/www.northernantibiotics.com\/index2.php?pageid=3&lang=em."},{"key":"ref_177","unstructured":"Vaara, M., and Vaara, T. Novel derivatives of polymyxin B, a review on the NAB compounds. Available online:http:\/\/www.northernantibiotics.com\/kuvat\/NAB%20Technical%20Info%20Sheet%20Nov%202010.pdf."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.2174\/09298673113209990185","article-title":"The renaissance of polymyxins","volume":"20","author":"Kadar","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/jac\/dkt039","article-title":"Novel derivatives of polymyxins","volume":"68","author":"Vaara","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_180","unstructured":"Cubist Pharmaceuticals Cubist products and pipeline. Available online:http:\/\/www.cubist.com\/products\/."},{"key":"ref_181","unstructured":"Cubist Pharmaceuticals Study of CB-183,315 in patients with Clostridium difficile associated diarrhea. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01597505."},{"key":"ref_182","unstructured":"Cubist Pharmaceuticals A study of CB-183,315 in patients with Clostridium difficile associated diarrhea. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01598311."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1128\/AAC.00057-12","article-title":"In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile","volume":"56","author":"Mascio","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1021\/ja970895o","article-title":"WAP-8294A2, a novel anti-MRSA antibiotic produced by Lysobacter sp","volume":"119","author":"Kato","year":"1997","journal-title":"J. Am. Chem. Soc."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ja.2011.9","article-title":"A new anti-MRSA antibiotic complex, WAP-8294A II. Structure characterization of minor components by ESI LCMS and MS\/MS","volume":"64","author":"Kato","year":"2011","journal-title":"J. Antibiot. (Tokyo)"},{"key":"ref_186","unstructured":"Pharma Japan aRigen licenses novel anti-MRSA to GCC in South Korea. Available online:http:\/\/www.pharma-japan.com\/."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1093\/jac\/dkq375","article-title":"Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance","volume":"65","author":"Emrich","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1128\/AAC.00833-10","article-title":"In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions","volume":"55","author":"Stubbings","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1128\/AAC.00641-06","article-title":"The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase","volume":"50","author":"Bhagwat","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/AAC.01150-08","article-title":"In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types","volume":"53","author":"Bhagwat","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_191","unstructured":"Zhu, D., and Hoshino, Y.K.K. (2012, January 12). DS-8587, A new generation of broad spectrum quinolone: In vitro antibacterial activities against Chinese clinical isolates. Proceedings of 52nd International Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA."},{"key":"ref_192","unstructured":"Achillion Pharmaceuticals, Inc. SEC filling form 10-Q quarterly report filed August 7, 2013. Available online:http:\/\/ir.achillion.com\/secfiling.cfm?filingID=1193125\u201313\u2013324297."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1128\/AAC.00862-10","article-title":"In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models","volume":"55","author":"Reyes","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1128\/AAC.00624-11","article-title":"Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects","volume":"55","author":"Cass","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_195","unstructured":"Basilea Pharmaceutica Exploratory programs. Available online:http:\/\/www.basilea.com\/Research\/Anti-infectives-research\/."},{"key":"ref_196","unstructured":"Trius Therapeutics TR-701 FA vs. linezolid for the treatment of acute bacterial skin and skin structure infections. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01170221."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bmc.2012.11.036","article-title":"Recent development of potent analogues of oxazolidinone antibacterial agents","volume":"21","author":"Michalska","year":"2013","journal-title":"Biorg. Med. Chem."},{"key":"ref_198","unstructured":"Cubist Pharmaceuticals Cubist Announces Submission of New Drug Application for Investigational Antibiotic Tedizolid for Treatment of Serious Skin Infections, Cubist Pharmaceuticals."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1128\/AAC.00948-12","article-title":"A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections","volume":"56","author":"Noel","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_200","unstructured":"Paratek Pharmaceuticals, Inc. Form S-1 Registration Statement under the Securities Act of 1933\u2014Paratek Pharmaceuticals, Inc.. Available online:http:\/\/www.sec.gov\/Archives\/edgar\/data\/1037643\/000119312512406909\/d386058ds1.htm#toc386058_10."},{"key":"ref_201","unstructured":"Tetraphase Pharmaceuticals Efficacy and safety study of eravacycline compared with ertapenem in complicated intra-abdominal infections. Available online:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01844856."},{"key":"ref_202","unstructured":"Tetraphase Pharmaceuticals (2013). Tetraphase Outlines Plans for Phase 3 Clinical Trial of Eravacycline IV\/Oral in Complicated Urinary Tract Infections, Tetraphase Pharmaceuticals."},{"key":"ref_203","unstructured":"Nabriva (2013). Nabriva Therapeutics Retains BC-3781 Rights as Forest Collaboration Elapses, Nabriva."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijantimicag.2013.05.010","article-title":"In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens","volume":"42","author":"Hornsey","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1128\/AAC.01737-10","article-title":"Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with Tazobactam against enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes","volume":"55","author":"Sader","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_206","unstructured":"Zhang, S., Chuong, L.I.M.C., Khang, I.C., Alsup, A., Li, T., Arya, A., He, Y., Yin, N., Rock, J., and Abel, C. (2012, January 10). In Vivo efficacy of CB-027 against methicillin-resistant Staphylococcus aureus, and ceftazidime-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae infections in mice. Proceedings of 52nd International Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: Results of a randomized, double-blind, Phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: A novel cephalosporin\/ \u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/CMR.00033-13","article-title":"Investigational antimicrobial agents of 2013","volume":"26","author":"Pucci","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_210","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_211","unstructured":"Maiti, S.N., Ling, D.N.R., Ha, C.M., Ganguly, B., Ou, L., Shan, R., Singh, R., Kully, M., Khan, J., and Salama, S.M. (2013, January 12). Design, synthesis and structure activity relationship of novel substituted amides containing diaza bicyclic heterocyclic compounds as broad-spectrum \u03b2-lactamase inhibitors. Proceedings of 53nd International Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, USA."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: A comparative review of Dalbavancin, Oritavancin and Telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"ref_213","unstructured":"The Medicines Company FDA Grants QIDP designation to the medicines company\u2019s investigational antibiotic oritavancin. Available online:http:\/\/ir.themedicinescompany.com\/phoenix.zhtml?c=122204&p=irol-newsArticle&ID=1875172&highlight=."},{"key":"ref_214","unstructured":"Goodman, L.S., and Gilman, A. (2011). Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics, McGraw-Hill Professional. [12th ed.]."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/2\/4\/500\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:51:11Z","timestamp":1760219471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/2\/4\/500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":214,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,12]]}},"alternative-id":["antibiotics2040500"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics2040500","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}